Supernus Pharmaceuticals (SUPN) Capital Expenditures (2011 - 2026)
Supernus Pharmaceuticals (SUPN) posted quarterly Capital Expenditures of $568000.0 for Q2 2026, up 24.84% year-over-year from $455000.0 in Q2 2025, and up 33.02% on a QoQ basis from $427000.0 in Q4 2025.
Supernus Pharmaceuticals (SUPN) Capital Expenditures (2011 - 2026) Analysis & Trends
Supernus Pharmaceuticals has reported Capital Expenditures for 15 years, with the latest figure at $568000.0 in Q2 2026.
- Capital Expenditures for Q2 2026 came in at $568000.0, up 24.84% year-over-year; the trailing twelve-month figure through Jun 2026 was $1.1 million (down 5.94% YoY), and the FY2025 annual result was $1.3 million, up 84.55% from the prior year.
- Capital Expenditures grew to $568000.0 in Q2 2026, from $427000.0 in the prior quarter.
- Over five years, Capital Expenditures peaked at $851000.0 in Q1 2022 and troughed at -$271000.0 in Q2 2022.
- A 5-year average of $224625.0 and a median of $206500.0 in 2024 frame the typical range for Capital Expenditures.
- The widest annual swing landed in 2023, when Capital Expenditures tumbled 67.33%; it then surged 691.67% in 2024.
- A 5-year view of Capital Expenditures shows it stood at -$168000.0 in 2022, then soared by 78.57% to -$36000.0 in 2023, then surged by 691.67% to $213000.0 in 2024, then jumped by 100.47% to $427000.0 in 2025, then soared by 33.02% to $568000.0 in 2026.
- Per Business Quant data, the three most recent Capital Expenditures figures were $568000.0 in Q2 2026, $427000.0 in Q4 2025, and $129000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.94 Bn | 42.97 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.08 Bn | 39.43 Bn | 2.15 Bn | 104.00 Mn |
| 3 | Zoetis | 31.54 Bn | 29.87 Bn | 1.05 Bn | 117.00 Mn |
| 4 | Takeda Pharmaceutical | 28.60 Bn | 22.80 Bn | 5.10 Bn | -337.60 Mn |
| 5 | United Therapeutics | 22.12 Bn | 19.46 Bn | 683.80 Mn | 108.00 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | 52.80 Mn |
| 7 | Neurocrine Biosciences | 15.50 Bn | 15.11 Bn | 935.80 Mn | 7.80 Mn |
| 8 | Elanco Animal Health | 11.69 Bn | 11.16 Bn | 798.00 Mn | 33.00 Mn |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.96 Bn | - | - |
| 10 | Supernus Pharmaceuticals | 2.74 Bn | 2.37 Bn | 185.39 Mn | 568,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 568,000.00 |
| Jun 30, 2026 | 568,000.00 |
| Dec 31, 2025 | 427,000.00 |
| Dec 31, 2025 | 427,000.00 |
| Sep 30, 2025 | 129,000.00 |
| Sep 30, 2025 | 129,000.00 |
| Jun 30, 2025 | 455,000.00 |
| Jun 30, 2025 | 455,000.00 |
| Mar 31, 2025 | 327,000.00 |
| Mar 31, 2025 | 327,000.00 |
| Dec 31, 2024 | 213,000.00 |
| Dec 31, 2024 | 213,000.00 |
| Sep 30, 2024 | 200,000.00 |
| Sep 30, 2024 | 200,000.00 |
| Jun 30, 2024 | 64,000.00 |
| Jun 30, 2024 | 64,000.00 |
| Mar 31, 2024 | 248,000.00 |
| Mar 31, 2024 | 248,000.00 |
| Dec 31, 2023 | -36,000.00 |
| Dec 31, 2023 | -36,000.00 |